Drug intelligence / Profile preview

levocarnitine + cilostazol

Development stage: Unknown
Lead developer: CPC Clinical Research
Modality: Small Molecules
Administration: Oral

Overview

levocarnitine + cilostazol is a combination therapy evaluated by CPC Clinical Research (Colorado Prevention Center) for the treatment of intermittent claudication in patients with peripheral artery disease (PAD). Levocarnitine (L-carnitine) is an endogenous amino acid derivative that facilitates the transport of long-chain fatty acids into the mitochondria for beta-oxidation, addressing metabolic deficiencies and the accumulation of short-chain acylcarnitines in ischemic muscle. Cilostazol is a phosphodiesterase 3 (PDE3) inhibitor that provides vasodilatory and antiplatelet effects. The Phase 4 ECLECTIC trial (NCT00822172) investigated the efficacy and safety of adding 1 g of levocarnitine twice daily to a standard cilostazol regimen to improve peak walking time and quality of life in symptomatic PAD patients.

Other names: levocarnitine-Colorado Prevention Center-intermittent claudicationL-carnitine + cilostazollevocarnitine tartrate + cilostazolECLECTIC

Targets

SLC7A1 (Cationic amino acid transporter 1)PDE3A (Phosphodiesterase 3A)CPT2 (Carnitine O-palmitoyltransferase 2)

Beyond the preview

Go deeper on levocarnitine + cilostazol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on levocarnitine + cilostazol.

Explore the full profile